巴曲酶治疗急性缺血性脑卒中患者的临床疗效

The clinical efficacy of Batroxobin in Treatment of Acute Ischemic Stroke Patients

目的探讨应用巴曲酶治疗急性缺血性脑卒中(CIS)患者的临床疗效。方法选取2014年1月至2015年6月期间黑龙江省医院收治的CIS患者64例作为研究对象,将其采用随机数字表法分为研究组与对照组,各32例。对照组患者应用常规治疗,研究组患者应用巴曲酶治疗,对比两组患者的治疗效果与安全性。结果研究组患者的治疗总有效率明显高于对照组,差异有统计学意义(P<0.05);治疗前两组患者的MRS与NIHSS评分比较差异均无统计学意义(均P>0.05),治疗后24 h及7 d时,研究组患者MRS与NIHSS评分均显著低于对照组,差异均有统计学意义(均P<0.05);且治疗后研究组血浆纤维蛋白原(FIB)水平显著低于对照组,差异均有统计学意义(均P<0.05)。两组患者治疗期间均未见血、尿、便常规检查及肝肾功能检查异常,均未发生出血反应,无主诉或观察到不良反应发生。结论巴曲酶治疗CIS可提高临床疗效,能够快速、有效地改善患者的神经功能,且不良反应少,不增加出血风险,用药安全可靠。

Objective To evaluate the clinical efficacy of batroxobin acute ischemic stroke（CIS） patients.Methods January 2014 to June 2015 during the CIS Heilongjiang Provincial Hospital admitted 64 patients as research subjects will be divided into study group and the control group,which uses random number table,32 cases in each.The control group of patients with conventional treatment,the study group patients Batroxobin,compared two groups of patients with the therapeutic effect and safety.Results Study group of patients with total effective rate was significantly higher,the difference was statistically significant（P〈0.05）;two groups of patients before treatment with MRS NIHSS score difference was not statistically significant（P〈0.05）,treatment after 24 h and 7 d,the MRS study patients with NIHSS scores were significantly lower than the control group,the differences were statistically significant（P〈0.05）; and the post-treatment of plasma fibrinogen（FIB） were significantly lower in the control group,the differences were statistically significant（P〈0.05）.During the two groups of patients were not to see blood,urine,feces routine examination, liver and kidney function tests abnormal bleeding reactions did not occur,or no complaints of adverse reactions were observed.Conclusion Batroxobin CIS can improve the clinical efficacy,it is possible to quickly and effectively improve neurological function in patients,and fewer adverse reactions,without increasing the risk of bleeding, medication safety and reliability.